CD47-signal regulatory protein-α (SIRPα) interactions form a barrier for antibody-mediated tumor cell destruction

Proceedings of the National Academy of Sciences of the United States of America

Volumn 108, Issue 45, 2011, Pages 18342-18347

  Zhao, Xi Wen ^a   Van Beek, Ellen M ^a   Schornagel, Karin ^a   Van Der Maaden, Hans ^b   Van Houdt, Michel ^a   Otten, Marielle A ^c   Finetti, Pascal ^d   Van Egmond, Marjolein ^e   Matozaki, Takashi ^f   Kraal, Georg ^e   Birnbaum, Daniel ^d   Van Elsas, Andrea ^b   Kuijpers, Taco W ^a   Bertucci, Francois ^d   Van Den Berg, Timo K ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b NV ORGANON   (Netherlands)

^c UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^d INSTITUT PAOLI CALMETTES   (France)

^e VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^f GUNMA UNIVERSITY   (Japan)

Author keywords

Antibody dependent cellular cytotoxicity; Fc receptor; Immunoreceptor; Neutrophil

Indexed keywords

CD47 ANTIGEN; REGULATOR PROTEIN; SIGNAL REGULATORY PROTEIN ALPHA; TRASTUZUMAB; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE MARROW CELL; BREAST CANCER; CANCER CELL DESTRUCTION; CANCER PATIENT; FEMALE; GENE EXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MELANOMA CELL; MOUSE; NONHUMAN; PHAGOCYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INTERACTION; TREATMENT RESPONSE; TUMOR CELL DESTRUCTION;

ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; ANTIGENS, CD47; ANTINEOPLASTIC AGENTS; FEMALE; FLOW CYTOMETRY; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, INBRED C57BL; RECEPTORS, IMMUNOLOGIC; SIGNAL TRANSDUCTION;

MUS;

EID: 81055145277     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1106550108     Document Type: Article

References (37)

1. Glennie MJ, van de Winkel JG (2003) Renaissance of cancer therapeutic antibodies. Drug Discov Today 8:503-510. (Pubitemid 36724584)
2. Oldham RK, Dillman RO (2008) Monoclonal antibodies in cancer therapy: 25 years of progress. J Clin Oncol 26:1774-1777.
3. Strome SE, Sausville EA, Mann D (2007) A mechanistic perspective of monoclonal antibodies in cancer therapy beyond target-related effects. Oncologist 12:1084-1095. (Pubitemid 350007020)
4. Clynes RA, Towers TL, Presta LG, Ravetch JV (2000) Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nat Med 6:443-446. (Pubitemid 30208162)
5. Barok M, et al. (2007) Trastuzumab causes antibody-dependent cellular cytotoxicity-mediated growth inhibition of submacroscopic JIMT-1 breast cancer xenografts despite intrinsic drug resistance. Mol Cancer Ther 6:2065-2072. (Pubitemid 47052497)
6. 2 fragments of a mixture of three monoclonal anti-Her-2 antibodies. Clin Cancer Res 10:3542-3551.
7. Lanier LL (2005) NK cell recognition. Annu Rev Immunol 23:225-274.
8. van Spriel AB, van Ojik HH, Bakker A, Jansen MJ, van de Winkel JG (2003) Mac-1 (CD11b/CD18) is crucial for effective Fc receptor-mediated immunity to melanoma. Blood 101:253-258. (Pubitemid 36025915)
9. Musolino A, et al. (2008) Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer. J Clin Oncol 26:1789-1796.
10. Fujioka Y, et al. (1996) A novel membrane glycoprotein, SHPS-1, that binds the SH2- domain-containing protein tyrosine phosphatase SHP-2 in response to mitogens and cell adhesion. Mol Cell Biol 16:6887-6899. (Pubitemid 26389748)
11. Kharitonenkov A, et al. (1997) A family of proteins that inhibit signalling through tyrosine kinase receptors. Nature 386:181-186. (Pubitemid 27131446)
12. Adams S, et al. (1998) Signal-regulatory protein is selectively expressed by myeloid and neuronal cells. J Immunol 161:1853-1859.
13. van Beek EM, Cochrane F, Barclay AN, van den Berg TK (2005) Signal regulatory proteins in the immune system. J Immunol 175:7781-7787. (Pubitemid 41798335)
14. Barclay AN, Brown MH (2006) The SIRP family of receptors and immune regulation. Nat Rev Immunol 6:457-464.
15. Jiang P, Lagenaur CF, Narayanan V (1999) Integrin-associated protein is a ligand for the P84 neural adhesion molecule. J Biol Chem 274:559-562.
16. Seiffert M, et al. (2001) Signal-regulatory protein α (SIRPα) but not SIRPβ is involved in T-cell activation, binds to CD47 with high affinity, and is expressed on immature CD34(+)CD38(-) hematopoietic cells. Blood 97:2741-2749.
17. Vernon-Wilson EF, et al. (2000) CD47 is a ligand for rat macrophage membrane signal regulatory protein SIRP (OX41) and human SIRPα 1. Eur J Immunol 30:2130-2137. (Pubitemid 30655751)
18. Timms JF, et al. (1998) Identification of major binding proteins and substrates for the SH2-containing protein tyrosine phosphatase SHP-1 in macrophages. Mol Cell Biol 18: 3838-3850. (Pubitemid 28287907)
19. Oldenborg PA, et al. (2000) Role of CD47 as a marker of self on red blood cells. Science 288:2051-2054.
20. Olsson M, Bruhns P, Frazier WA, Ravetch JV, Oldenborg PA (2005) Platelet homeostasis is regulated by platelet expression of CD47 under normal conditions and in passive immune thrombocytopenia. Blood 105:3577-3582. (Pubitemid 40628203)
21. Yamao T, et al. (2002) Negative regulation of platelet clearance and of the macrophage phagocytic response by the transmembrane glycoprotein SHPS-1. J Biol Chem 277:39833-39839.
22. Ishikawa-Sekigami T, et al. (2006) SHPS-1 promotes the survival of circulating erythrocytes through inhibition of phagocytosis by splenic macrophages. Blood 107:341-348. (Pubitemid 43053561)
23. Okazawa H, et al. (2005) Negative regulation of phagocytosis in macrophages by the CD47-SHPS-1 system. J Immunol 174:2004-2011. (Pubitemid 40223942)
24. Oldenborg PA, Gresham HD, Lindberg FP (2001) CD47-signal regulatory protein α (SIRPα) regulates Fcγ and complement receptor-mediated phagocytosis. J Exp Med 193:855-862.
25. Takenaka K, et al. (2007) Polymorphism in Sirpa modulates engraftment of human hematopoietic stem cells. Nat Immunol 8:1313-1323. (Pubitemid 350138972)
26. van den Berg TK, van der Schoot CE (2008) Innate immune 'self' recognition: A role for CD47-SIRPα interactions in hematopoietic stem cell transplantation. Trends Immunol 29:203-206.
27. Chao MP, et al. (2010) Anti-CD47 antibody synergizes with rituximab to promote phagocytosis and eradicate non-Hodgkin lymphoma. Cell 142:699-713.
28. Hara I, Takechi Y, Houghton AN (1995) Implicating a role for immune recognition of self in tumor rejection: Passive immunization against the brown locus protein. J Exp Med 182:1609-1614.
29. Harris LN, et al. (2007) Predictors of resistance to preoperative trastuzumab and vinorelbine for HER2-positive early breast cancer. Clin Cancer Res 13:1198-1207. (Pubitemid 46424061)
30. Latour S, et al. (2001) Bidirectional negative regulation of human T and dendritic cells by CD47 and its cognate receptor signal-regulator protein-α: Down-regulation of IL- 12 responsiveness and inhibition of dendritic cell activation. J Immunol 167: 2547-2554. (Pubitemid 32768881)
31. Chao MP, et al. (2011) Therapeutic antibody targeting of CD47 eliminates human acute lymphoblastic leukemia. Cancer Res 71:1374-1384.
32. Hatherley D, Graham SC, Harlos K, Stuart DI, Barclay AN (2009) Structure of signalregulatory protein α: A link to antigen receptor evolution. J Biol Chem 284: 26613-26619.
33. McWhirter JR, et al. (2006) Antibodies selected from combinatorial libraries block a tumor antigen that plays a key role in immunomodulation. Proc Natl Acad Sci USA 103:1041-1046. (Pubitemid 43212218)
34. Kretz-Rommel A, et al. (2007) CD200 expression on tumor cells suppresses antitumor immunity: New approaches to cancer immunotherapy. J Immunol 178:5595-5605. (Pubitemid 46674355)
35. Kretz-Rommel A, et al. (2008) Blockade of CD200 in the presence or absence of antibody effector function: Implications for anti-CD200 therapy. J Immunol 180:699-705.
36. Bertucci F, et al. (2006) Gene expression profiling shows medullary breast cancer is a subgroup of basal breast cancers. Cancer Res 66:4636-4644.
37. Sabatier R, et al. (2011) A gene expression signature identifies two prognostic subgroups of basal breast cancer. Breast Cancer Res Treat 126:407-420.